We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Arch Pharma Labs has filed the application
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Subscribe To Our Newsletter & Stay Updated